Impact of sex on insulin secretion in cystic fibrosis

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages 1767-1773

  Coriati, Adèle ^a,b   Belson, Linda ^a,b   Ziai, Sophie ^a,b   Haberer, Eleonore ^a,b   Gauthier, Marie Soleil ^a,b   Mailhot, Geneviève ^b,c   Coderre, Lise ^a,b   Berthiaume, Yves ^a,b,c   Rabasa Lhoret, Rémi ^a,b,c,d  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d Montreal Diabetes Research Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; BLOOD GLUCOSE; CYSTIC FIBROSIS; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INSULIN; MALE; SEX FACTORS;

EID: 84899898142     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2756     Document Type: Article

References (38)

1. Cystic Fibrosis Canada. Toronto, Ontario, Canada: Canadian Cystic Fibrosis Registry. Annual Report; 2011. Available at http://www. cysti cfibrosis.ca/wp-content/uploads/2013/10/Registry2011FINAL OnlineEN.pdf. Accessed January 30, 2014.
2. Costa M, Potvin S, Berthiaume Y, et al. Diabetes: a major co-morbidity of cystic fibrosis. Diabetes Metab. 2005;31(3 Pt 1):221-232
3. Moran A, Becker D, Casella SJ, et al. CFRD Consensus Conference Committee. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related di abetes: a technical review. Diabetes Care 2010;33(12):2677-2683.
4. Cucinotta D, De Luca F, Scoglio R, et al. Factors affecting diabetes mellitus onset in cystic fibrosis: evidence from a 10-year fol low-up study. Acta Paediatr. 1999;88(4):389-393.
5. Arrigo T, Cucinotta D, Conti Nibali S, et al. Longitudinal evaluation of glucose tolerance and insulin secretion in non-diabetic children and adolescents with cystic fibrosis: results of a two-year follow-up. Acta Paediatr. 1993;82(3):249-253.
6. Iannucci A, Mukai K, Johnson D, Burke B. Endocrine pancreas in cystic fibrosis: an immunohistochemical study. Hum Pathol. 1984; 15(3):278-284.
7. Couce M, O'Brien TD, Moran A, Roche PC, Butler PC. Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. J Clin Endo Metab. 1996;81:1267-1272.
8. Milla CE Billings J Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis Di abetes Care. 2005 28(9) 2141-2144.
9. Sims EJ, GreenMW,MehtaA. Decreased lung function in female but not male subjects with established cystic fibrosis-related diabetes. Diabetes Care. 2005;28(7):1581-1587.
10. Moran A, Dunitz J, Nathan B, Sa eed A, Holme B, ThomasW.Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):1626-1631.
11. Public Health Agency of Canada. Diabetes in Can ada: facts and figures from a public health perspective using 2008/2009 data from the Canadian Chronic Disease Surveillance System. Ottawa: Public Health Agency of Canada; 2011.
12. Rome S, Clément K, Rabasa-Lho ret R, et al. Microarray profiling of human skeletal muscle reveals that insulin regulates approximately 800 genes during a hyperinsulinemic clamp. J Biol Chem. 2003; 278(20):18063-18068.
13. Lanng S, Thorsteinsson B, Nerup J, KoChang C.H. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr. 1994;83(8):849-853.
14. Hameed S, Morton JR, Field PI, et al. Once daily insulin detemir in cystic fibrosis with insulin deficiency. Arch Dis Child 2012;97(5): 464-7.
15. Kolousková S, Zemková D, Bartosová J, et al. Low-dose insulin therapy in patients with cystic fibrosis and early-stage insulinopenia prevents deterioration of lung function: a 3-year prospective study. J Pediatr Endocrinol Metab. 2011;24(7-8):449-454.
16. Hammana I, Malet A, Costa M, et al. Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis. Diabetes Metab. 2007;33(3): 213-219.
17. Canadian Diabetes Association. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2008;32(suppl 1):S10-S13.
18. Stumvoll M, Van Haef ten T, Fritsche A, Gerich J. Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. Diabetes Care. 2001;24(4): 796-797.
19. Ziai S, Belson L, Hammana I, Berthiaume Y, Rabasa-Lhoret R. Validation of insulin secretion indices in cystic fibrosis. J Cyst Fibros. 2011;10(2):145.
20. Poitout V, Robertson RP. A n integrated view of-cell dysfunction in type-II diabetes. Annu Rev Med. 1996;47:69-83.
21. Stevenson JC, Crook D, Godsland IF, Collins P, Whitehead MI. Hormone replacement therapy and the cardiovascular system. Nonlipid effects. Drugs. 1994;47(suppl 2):35-41.
22. Alonso-Magdalena P, Ropero AB, Carrera MP, et al. Pancreatic insulin content regulation by the estrogen receptor ER-. PLoS One. 2008;3(4):e2069.
23. Chen H, Guo JH, Lu YC, et al. Impaired CFTR-dependent amplification of FSH-stimulated estrogen production in cystic fibrosis and PCOS. J Clin Endocrinol Metab. 2012;97(3):923-932.
24. Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev. 2013;34(3):309-338.
25. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18(6):774-800.
26. Hollander FM, De Roos NM, De Vries JH, Van Berkhout FT. Assessment of nutritional status in adult patients with cystic fibrosis: whole-body bioimpedance vs body mass index, skinfolds, and legto-leg bioimpedance. J Am Diet Assoc. 2005;105(4):549-555 .
27. Mohan K, Israel KL, Miller H, Grainger R, Ledson MJ, Walshaw MJ. Long-term effect of insulin treatment in cystic fibrosis-related diabetes. Respiration. 2008;76(2):181-186.
28. Tuut M, Hense HW. Smoking, other risk factors and fibrinogen levels. Evidence of effect modification. Ann Epidemiol. 2001;11(4): 232-238.
29. Danaei G Finucane MM Lu Y et al. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980 systematic analysis of health exam ination surveys and epidemiological studies with 370 countryyears and 2-7 million participants. Lancet. 2011 378(9785) 31-40.
30. Soeters MR, Sauerwein HP, Groener JE, et al. Gender-related differences in the metabolic response to fasting. J Clin Endocrinol Metab. 2007;92(9):3646-3652.
31. Haymond MW, Karl IE, Clarke WL, Pagliara AS, Santiago JV. Differences in circulating gluconeo genic substrates during shortterm fasting in men, women, and children. Metabolism. 1982; 31(1):33-42.
32. Ahmed-Sorour H, Bailey CJ. Role of ovarian hormones in the longterm control of glucose homeostasis, glycogen formation and gluconeogenesis. Ann Nutr Metab. 1981;25(4):208-212.
33. Basu R, Dalla Man C, Campioni M, et al. Effects of age and sex on postprandial glucose metabolism: dif ferences in glucose turnover, insulin secretion, insulin action, and hepatic insulin extraction. Diabetes. 2006;55(7):2001-2014.
34. Louet JF, LeMay C, Mauvais-Jarvis F. Antidiabetic actions of estrogen: insight from human and genetic mouse models. Curr Atheroscler Rep. 2004;6(3):180-185.
35. Adam TC, Westerterp-Plantenga MS. Nutrient-stimulated GLP-1 release in normal-weight men and women. Horm Metab Res. 2005; 37(2):111-117.
36. Hammana I, Potvin S, Tardif A, Berthiaume Y, Coderre L, Rabasa-Lhoret R. Validation of insulin secretion indices in cystic fibrosis patient s. J Cyst Fibros. 2009;8(6):378-381.
37. Elbein SC, Hasstedt SJ, Wegner K, Kahn SE. Heritability of pancreatic-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab. 1999;84: 1398-1403.
38. ByrneMM,Sturis J, Sobel RJ, Polonsky KS. Elevated plasma glucose 2 h postchallenge predicts defects in-cell function. Am J Physiol. 1996;270:E572-E579.